Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC
In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.